Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Atezolizumab in NSCLC
NCT03023423Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2016
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of daratumumab in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Dec 2016; status: completed.
02
Drugs
daratumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03023423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023423.